scholarly journals Histopathologic and Molecular Biomarkers of PD-1/PD-L1 Inhibitor Treatment Response Among Patients with Microsatellite Instability‒High Colon Cancer

2022 ◽  
Author(s):  
Jaewon Hyung ◽  
Eun Jeong Cho ◽  
Jihun Kim ◽  
Jwa Hoon Kim ◽  
Jeong Eun Kim ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Microsatellite Instability ◽  
Treatment Response ◽  
Molecular Biomarkers ◽  
Inhibitor Treatment

p14 methylation in human colon cancer is associated with microsatellite instability and wild-type p53

2003 ◽  
Vol 124 (3) ◽  
pp. 626-633 ◽  
Author(s):  
Lanlan Shen ◽  
Yutaka Kondo ◽  
Stanley R. Hamilton ◽  
Asif Rashid ◽  
Jean–Pierre J. Issa
Keyword(s):  
Colon Cancer ◽  
Microsatellite Instability ◽  
Human Colon ◽  
Wild Type ◽  
Human Colon Cancer ◽  
Wild Type P53

Sporadic Colon Cancer: Mismatch Repair Immunohistochemistry and Microsatellite Instability in Omani Subjects

2008 ◽  
Vol 53 (10) ◽  
pp. 2723-2731 ◽  
Author(s):  
Hassan Ashktorab ◽  
Hassan Brim ◽  
Marwa Al-Riyami ◽  
Anand Date ◽  
Kamla Al-Mawaly ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Microsatellite Instability ◽  
Mismatch Repair ◽  
Sporadic Colon Cancer

The impact of KRAS mutation, microsatellite instability, and tumor laterality on the prognosis of nonmetastatic colon cancer

Surgery ◽  
2021 ◽  
Author(s):  
Catherine G. Tran ◽  
Paolo Goffredo ◽  
Sarah L. Mott ◽  
Alexander Hart ◽  
Y. Nancy You ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Microsatellite Instability ◽  
Kras Mutation ◽  
The Impact ◽  
Tumor Laterality

p27KIPI Expression inversely correlates with microsatellite instability and TGF-β receptor type II mutations in sporadic colon cancer

1998 ◽  
Vol 114 ◽  
pp. A636
Author(s):  
Dong Feng Liu ◽  
William M Grady ◽  
Ashwani Rajput ◽  
Sanford Markowitz ◽  
Joseph Willis
Keyword(s):  
Colon Cancer ◽  
Microsatellite Instability ◽  
Receptor Type ◽  
Type Ii ◽  
Β Receptor ◽  
Sporadic Colon Cancer

scholarly journals Establishment and Validation of a Genetic Label Associated With M2 Macrophage Infiltration to Predict Survival in Colon Cancer Patients and Assist Immunotherapy

2021 ◽  
Author(s):  
Boyang Xu ◽  
Ziqi Peng ◽  
Guanyu Yan ◽  
Ningning Wang ◽  
Moye Chen ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Microsatellite Instability ◽  
Cancer Patients ◽  
Immune Cell ◽  
Checkpoint Inhibitors ◽  
Macrophage Infiltration ◽  
M2 Macrophage ◽  
High Morbidity ◽  
M2 Macrophages ◽  
Hub Genes

Abstract Background: Colon cancer is a kind of malignant tumor with high morbidity and mortality. Researchers have tried to interpret it from different perspectives and divide it into different subtypes in order to achieve individualized treatment. With the rise of immunotherapy, its value in the field of tumor has initially emerged. Based on the above background, from the perspective of immune infiltration, this study classified colon cancer according to the infiltration of M2 macrophages in patients with colon cancer and further explored it.Methods: Cibersort was used to analyze the level of immune cell infiltration in colon cancer patients in the TCGA database. WGCNA, Consensus Clustering analysis, Lasso analysis, and univariate KM analysis were used to screen and verify the hub genes associated with M2 macrophages. PCA was used to establish the M2 macrophage-related score—M2I Score. The correlation between M2I Score and somatic cell variation and microsatellite instability were analysed. Furthermore the correlation between M2 macrophage score and differences in immunotherapy sensitivity was also explored. Results: M2 macrophage infiltration was associated with poor prognosis. Four hub genes (ANKS4B, CTSD, TIMP1, and ZNF703) were selected as the progression-related genes associated with M2 macrophages. A stable and accurate M2I Score for M2 macrophages used in COAD was constructed based on four hub genes. M2I Score was positively correlated with tumor mutation load (TMB). The M2I Score of MSI-H group was higher than that of MSI-L group and MSS group. Combine with the TCIA database, we concluded that patients with a high M2I Score were more sensitive to PD-1 inhibitors and PD-1 inhibitors combined with CTLA-4 inhibitors. The low rating group may have better efficacy without immune checkpoint inhibitors or with CTLA4 inhibitors alone.Conclusion: Four prognostic hub genes associated with M2 macrophages were screened to establish the M2I Score and divided the patients into two subgroups: high M2I Score group and low M2I Score group. TMB, microsatellite instability and sensitivity to immunotherapy were higher in the high-rated group. PD-1 inhibitors or PD-1 combined with CTLA-4 inhibitors are preferred for patients in the high-rated group who are more sensitive to immunotherapy.

scholarly journals Outcomes Following Immune Checkpoint Inhibitor Treatment of Patients With Microsatellite Instability-High Cancers

JAMA Oncology ◽  
2020 ◽  
Vol 6 (7) ◽  
pp. 1068 ◽  
Author(s):  
Fausto Petrelli ◽  
Michele Ghidini ◽  
Antonio Ghidini ◽  
Gianluca Tomasello
Keyword(s):  
Microsatellite Instability ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor ◽  
Inhibitor Treatment

scholarly journals Biomarkers for Bladder Cancer Diagnosis and Surveillance: A Comprehensive Review

Diagnostics ◽  
2020 ◽  
Vol 10 (1) ◽  
pp. 39 ◽  
Author(s):  
Rui Batista ◽  
Nuno Vinagre ◽  
Sara Meireles ◽  
João Vinagre ◽  
Hugo Prazeres ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Treatment Response ◽  
Cancer Diagnosis ◽  
Complex Disease ◽  
Molecular Biomarkers ◽  
Clinical Staging ◽  
Response Monitoring ◽  
High Morbidity ◽  
Non Invasive

Bladder cancer (BC) ranks as the sixth most prevalent cancer in the world, with a steady rise in its incidence and prevalence, and is accompanied by a high morbidity and mortality. BC is a complex disease with several molecular and pathological pathways, thus reflecting different behaviors depending on the clinical staging of the tumor and molecular type. Diagnosis and monitoring of BC is mainly performed by invasive tests, namely periodic cystoscopies; this procedure, although a reliable method, is highly uncomfortable for the patient and it is not exempt of comorbidities. Currently, there is no formal indication for the use of molecular biomarkers in clinical practice, even though there are several tests available. There is an imperative need for a clinical non-invasive testing for early detection, disease monitoring, and treatment response in BC. In this review, we aim to assess and compare different tests based on molecular biomarkers and evaluate their potential role as new molecules for bladder cancer diagnosis, follow-up, and treatment response monitoring.

Sign in / Sign up

Export Citation Format

Share Document